Navigation Links
Perrigo Provides Update on Acquisition of Paddock Labs
Date:6/29/2011

ALLEGAN, Mich., June 29, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize  the regulatory approvals necessary to complete the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products.

Perrigo Chairman and CEO Joseph C. Papa stated, "We are looking forward to concluding the transaction as soon as possible. As we previously stated, we expect the transaction to be $0.25 accretive to adjusted earnings per share in fiscal year 2012. We have recently received a few additional questions from the Federal Trade Commission Staff and the Parties are working collaboratively with the Staff to answer these questions so that the FTC may conclude its review.  Since the close will now happen in our fiscal year 2012, we expect to incur $0.20 of deal-related intangible amortization and $0.15 of other acquisition-related costs, making it approximately $0.10 dilutive to GAAP earnings per share. Perrigo's stated goal of Return on Invested Capital accretion is expected to be achieved in fiscal 2013. This acquisition is an important step forward in executing Perrigo's strategy to expand our specialty portfolio of generic Rx products. It adds incremental scale, as well as excellent development and manufacturing capabilities across a spectrum of niche dosage forms. It solidifies Perrigo's leading position in the extended topical space and strengthens our ability to offer new products into the market. Paddock has a proven record for quality manufacturing with great customer service."

As previously highlighted, Perrigo expects to receive a significant tax benefit generated from the acquisition of Paddock's assets. The net present value of the tax benefit is estimated to be $95 million. Inclusive of the tax benefit, the total consideration for the acquisition is approximately $445 million.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
2. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
3. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
4. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
5. Perrigo Announces Settlement of Cutivate Lotion Litigation
6. Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers
7. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
8. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
9. Perrigo Company Announces Quarterly Dividend
10. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
11. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Australia Ophthalmic Lasers Market Outlook to 2022 ... Outlook to 2022", provides key market data on the ... millions of US dollars, volume (in units) and average ... Lasers and YAG Lasers. The report also provides ... these market segements, and global corporate-level profiles of the ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... offices in Pasco and Richland, is initiating a charity drive to support the ... from a recent automobile collision. , On October 29th of this year, ...
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
Breaking Medicine News(10 mins):